Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Epidemiological and Clinical Characteristics of COVID-19 Patients with Cancers: A Systematic Review and Meta-Analysis of Global Data

Xiangyi Kong, Yihang Qi, junjie Huang, Yang Zhao, Yongle Zhan, Xuzhen Qin, Zhihong Qi, Adejare (Jay) Atanda, Lei Zhang, Jing Wang, Yi Fang, Peng Jia, Asieh Golozar, View ORCID ProfileLin Zhang, Yu Jiang
doi: https://doi.org/10.1101/2020.08.20.20177311
Xiangyi Kong
1Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yihang Qi
1Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
junjie Huang
2jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Zhao
3Melbourne School of Population and Global Health, The University of Melbourne, Victoria 3100, Australia
4WHO Collaborating Centre on Implementation Research for Prevention & Control of NCDs, Victoria 3100, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongle Zhan
5School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuzhen Qin
6Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhihong Qi
6Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adejare (Jay) Atanda
7School of Community Health and Policy, Morgan State University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Zhang
8China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, Shanxi, 710061, PR China.
9Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia
10Central Clinical School, Faculty of Medicine, Monash University, Melbourne, Australia
11Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Wang
1Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jiangyu{at}pumc.edu.cn tony1982110{at}gmail.com Asieh.golozar{at}gmail.com jiapengff{at}hotmail.com fangyi{at}cicams.ac.cn wangjing{at}cicams.ac.cn
Yi Fang
1Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jiangyu{at}pumc.edu.cn tony1982110{at}gmail.com Asieh.golozar{at}gmail.com jiapengff{at}hotmail.com fangyi{at}cicams.ac.cn wangjing{at}cicams.ac.cn
Peng Jia
12Department of Land Surveying and Geo-Informatics, The Hong Kong Polytechnic University, Hong Kong, China
13International Institute of Spatial Lifecourse Epidemiology (ISLE), Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jiangyu{at}pumc.edu.cn tony1982110{at}gmail.com Asieh.golozar{at}gmail.com jiapengff{at}hotmail.com fangyi{at}cicams.ac.cn wangjing{at}cicams.ac.cn
Asieh Golozar
14Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore MD USA
15Regeneron Pharmaceuticals, NY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jiangyu{at}pumc.edu.cn tony1982110{at}gmail.com Asieh.golozar{at}gmail.com jiapengff{at}hotmail.com fangyi{at}cicams.ac.cn wangjing{at}cicams.ac.cn
Lin Zhang
5School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
16Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia
17Centre of Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lin Zhang
  • For correspondence: jiangyu{at}pumc.edu.cn tony1982110{at}gmail.com Asieh.golozar{at}gmail.com jiapengff{at}hotmail.com fangyi{at}cicams.ac.cn wangjing{at}cicams.ac.cn
Yu Jiang
5School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jiangyu{at}pumc.edu.cn tony1982110{at}gmail.com Asieh.golozar{at}gmail.com jiapengff{at}hotmail.com fangyi{at}cicams.ac.cn wangjing{at}cicams.ac.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Summary Background Data on the prevalence of cancer in coronavirus disease 2019 (COVID-19)-infected patients and the severe illness incidence and mortality of COVID-19 patients with cancers remains unclear.

Methods We systematically searched PubMed, Embase, Cochrane Library, and Web of Science, from database inception to July 15, 2020, for studies of patients with COVID-19 infection that had available comorbidity information on cancer. The primary endpoint was the pooled prevalence of cancer in COVID-19 patients and the secondary endpoint was the outcomes of COVID-19-infected cancer patients with incidence of severe illness and death rate. We calculated the pooled prevalence and corresponding 95% confidence intervals (95% CIs) using a random-effects model, and performed meta-regression analyses to explore heterogeneity. Subgroup analyses were conducted based on continent, country, age, sample size and study design.

Findings A total of 107 eligible global studies were included in the systematic review. 90 studies with 94,845 COVID-19 patients in which 4,106 patients with cancer morbidity were included in the meta-analysis for prevalence of cancer morbidity among COVID-19 patients. 21 studies with 70,969 COVID-19 patients in which 3,351 patients with cancer morbidity who had severe illness or death during the studies. The overall prevalence of cancer among the COVID-19 patients was 0.07 (95% CI 0.05∽0.09). The cancer prevalence in COVID-19 patients of Europe (0.22, 95% CI 0.17∽0.28) was higher than that in Asia Pacific (0.04, 95% CI 0.03∽0.06) and North America (0.05, 95% CI 0.04∽0.06). The prevalence of COVID-19-infected cancer patients over 60 years old was 0.10 (95% CI 0.07∽0.14), higher than that of patients equal and less than 60 years old (0.05, 95% CI 0.03∽0.06). The pooled prevalence of severe illness among COVID-19 patients with cancers was 0.35 (95% CI 0.27∽0.43) and the pooled death rate of COVID-19 patients with cancers was 0.18 (95% CI 0.14∽0.18). The pooled incidence of severe illness of COVID-19 patients with cancers from Asia Pacific, Europe, and North America were 0.38(0.24, 0.52), 0.36(0.17, 0.55), and 0.26(0.20, 0.31), respectively; and the pooled death rate from Asia Pacific, Europe, and North America were 0.17(0.10, 0.24), 0.26(0.13, 0.39), and 0.19(0.13, 0.25), respectively.

Interpretation To our knowledge, this study is the most comprehensive and up-to-date metaanalysis assessing the prevalence of cancer among COVID-19 patients, severe illness incidence and mortality rate. The prevalence of cancer varied significantly in geographical continents and age. The COVID-19 patients with cancer were at-risk for severe illness and a high death rate. The European COVID-19 patients had the highest cancer prevalence among the three continents examined and were also the most likely to progress to severe illness and death. Although the Asia Pacific COVID-19 patients had the lowest cancer prevalence, their severe illness rate was similar to that of European’s.

Evidence before this study Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly discovered coronavirus, which leads to respiratory illness and can be transmitted from person to person. As the infection has become widespread, concern for the influence of COVID-19 on patients with cancer has grown. Previous studies suggest that patients with a history of active malignancy might be at increased risk for COVID-19, developing COVID-19-related complications and having a poorer prognosis. Until now, however, few studies explored the following two questions: 1) what is the estimated prevalence of cancer patients with COVID-19 infection; and 2) do COVID-19-infected cancer-patients have distinct clinical courses and worse outcomes compared with COVID-19-infected patients without cancers. The latter is based on the former to further explore the characteristics of clinical outcomes of such patients. The clarification of these two questions will greatly help to understand the relationship between COVID-19 and cancer in terms of clinical epidemiology, and thus facilitate the formulation of targeted and relevant public health policies.

Added value of this study To our knowledge, this systematic review and meta-analysis of 107 studies is the most comprehensive and up-to-date assessing the prevalence of cancer among COVID-19 patients, the incidence of severe illness and mortality rate of COVID-19 patients with cancers. We provided a relatively accurate overall cancer prevalence among the all COVID-19 patients (7%), stratified by geographical continent, country, age, study sample size, and study design type. We also presented the pooled severe illness and mortality rates stratified by continent. European COVID-19-infected cancer patients seemed the most likely to both develop cancer and progress to severe illness and death.

Implications of all the available evidence Our findings have reinforced important considerations of clinical care and emphasized the urgent unmet needs for COVID-19 patients with cancers using the pooled prevalence, incidence of severe illness, and death rates as evidence. Also, after comparing the cancer prevalence, incidence of severe illness, and death rate of COVID-19 patients from different continents, European population may require stronger control measures than the Asia Pacific and North American populations. In the future, as more data will be available, it will be interesting to further investigate the differences of sociodemographic and climcopathological features between COVID-19-infected patients with cancer and without cancer.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Beijing Municipal Natural Science Foundation (No. 7204293 and No. 7191009), the Special Research Fund for Central Universities, Peking Union Medical College (No. 3332019053), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2019B03 and No. LC2019L07), the Natural Science Foundation of China (No. 81872160), and National Key R&D Program of China (No. 2018YFC1315000 and No. 2018YFC1315003). The funders have no conflicts of interests. The funders of the study had no roles in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors have full access to all the data in the study and have final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College institutional review board approved this study as exempt.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data were abstracted from the published paper.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Epidemiological and Clinical Characteristics of COVID-19 Patients with Cancers: A Systematic Review and Meta-Analysis of Global Data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Epidemiological and Clinical Characteristics of COVID-19 Patients with Cancers: A Systematic Review and Meta-Analysis of Global Data
Xiangyi Kong, Yihang Qi, junjie Huang, Yang Zhao, Yongle Zhan, Xuzhen Qin, Zhihong Qi, Adejare (Jay) Atanda, Lei Zhang, Jing Wang, Yi Fang, Peng Jia, Asieh Golozar, Lin Zhang, Yu Jiang
medRxiv 2020.08.20.20177311; doi: https://doi.org/10.1101/2020.08.20.20177311
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Epidemiological and Clinical Characteristics of COVID-19 Patients with Cancers: A Systematic Review and Meta-Analysis of Global Data
Xiangyi Kong, Yihang Qi, junjie Huang, Yang Zhao, Yongle Zhan, Xuzhen Qin, Zhihong Qi, Adejare (Jay) Atanda, Lei Zhang, Jing Wang, Yi Fang, Peng Jia, Asieh Golozar, Lin Zhang, Yu Jiang
medRxiv 2020.08.20.20177311; doi: https://doi.org/10.1101/2020.08.20.20177311

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)